Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2024-03-14 Annual Report
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
Annual information form - English.pdf
Annual Report Classification · 95% confidence The document is titled 'Annual Information Form' for HLS Therapeutics Inc. dated March 13, 2024, and contains detailed sections such as company description, business development, share capital, dividends, directors and officers, auditor and audit committee information, risk factors, legal proceedings, and additional information. It includes comprehensive narrative and financial-related disclosures typical of an annual filing. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content aligns with an annual report providing a full overview of company activities and financial performance for the year ended December 31, 2023. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-03-14 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis for the Year Ended December 31, 2023' and contains detailed management commentary on financial results, business operations, product updates, and forward-looking statements. It references audited consolidated financial statements and includes financial metrics such as net loss, EBITDA, and other financial data. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content aligns with the typical Management Discussion and Analysis (MD&A) section that accompanies annual or interim financial reports. Therefore, the document fits the category of Management Reports (MDA), which provide detailed explanations of financial results, business trends, and outlook, rather than the full Annual Report (10-K) or other categories.
2024-03-14 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'Independent Auditor’s Report' and contains an auditor's opinion on the consolidated financial statements of HLS Therapeutics Inc. for the years ended December 31, 2023 and 2022. It includes detailed audit procedures, key audit matters, and the consolidated financial statements themselves, such as the statements of financial position and loss. The presence of detailed financial data and audit opinion indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial statements and notes, not just an announcement or certification. Therefore, the document fits the definition of an Audit Report / Information (AR). FY 2023
2024-03-14 English
News release - English.pdf
Annual Report Classification · 95% confidence The document is a detailed announcement of HLS Therapeutics' fiscal 2023 financial results, including revenue, EBITDA, net loss, and operational highlights. It contains comprehensive financial data for the full fiscal year and the fourth quarter, including product sales, royalty revenues, operating expenses, and cash flow. The document also discusses management changes, credit agreement amendments, and provides a 2024 outlook. Additionally, it announces a conference call to discuss these results. The presence of detailed financial statements and management discussion indicates this is a full financial report for the fiscal year, not just a brief earnings release or an announcement of a report. Therefore, the document fits the definition of an Annual Report (10-K) or equivalent comprehensive yearly financial report. Given the detailed financial data and analysis for the full fiscal year, the appropriate classification is Annual Report (10-K). FY 2023
2024-03-14 English
News release - English.pdf
Regulatory Filings
2024-02-29 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that the pharmaceutical product Vascepa is now reimbursed by British Columbia's Provincial Drug Plan and other health plans. It discusses a Product Listing Agreement (PLA) with BC PharmaCare and mentions reimbursement details. There is no financial data, no regulatory filing, no management or board changes, no earnings or annual report content, and no legal or merger information. The document is an update on product reimbursement and market access, which fits best under Capital/Financing Update (CAP) as it relates to financing and reimbursement activities impacting the company's commercial operations. The document length is 6311 characters, which is sufficient for a substantive announcement but does not contain financial statements or detailed financial analysis. Therefore, the classification is CAP with high confidence.
2024-02-06 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.